Comparison of sedation effect of midazolam and muscle haloperidol in treatment of agitation of patients referring to emergency

Phase 1

Conditions: Agitation.
Restlessness and agitation
R45.1

Registration Number: IRCT20200720048146N1

Lead Sponsor: Zahedan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: All

Target Recruitment: 120

Inclusion Criteria

Includes age 15 to 60 years
Class ?
ASA ?
Score above 28 on the agitation measurement scale

Exclusion Criteria

Patient dissatisfaction (or legal partner)
Unstable vital signs (blood pressure less than 90 mm Hg, heart rate below 60 and above 120 beats per minute, oxygen saturation level below 90%, level of consciousness less than agitation)
History of heart disease and liver and kidney failure
Pregnancy and lactation
The patient is very restless and has the potential to harm himself and others and can not wait for a response to intramuscular injection of the drug.
Poisoning with an unknown drug
A history of active seizures requires medication
Myasthenia Gravis
Bone marrow suppression
Patients with coagulation disorders such as hemophilia in whom intramuscular injection is contraindicated
Thyrotoxicosis
Hypersensitivity to midazolam or haloperidol

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Agitation. Timepoint: The patient is monitored for two hours after the injection. After 30, 60 and 15 minutes, they are measured for drug response (agitation control) and at the end of two hours for side effects. Method of measurement: Drug response rate is defined according to the agitation measurement scale (score less than 28).;Midazolam and haloperidol. Timepoint: At the beginning of the intervention. Method of measurement: Medications containing midazolam 5mg, or haloperidol 5mg, are prepared by block randomization. They are coded by the person in charge of the research, so that the doctor and the patient do not know the type of injectable drug. After obtaining the consent of the patient and having the desired criteria, the drugs are injected intramuscularly into the patient's left deltoid muscle with a 2 cc syringe.

Secondary Outcome Measures